Objective To study the way of blocking the father-child、mother-child transmission of HBV.Methods 387 fathers or mothers who were positive for HBV-DNA were divided into three groups according to the father and mother's HBV-DNA and anti-HBsAg. Then they were randomly divided into three groups,one group were treated by HBIG,the second group were treated by lamivudine,the third group were treated by HBIG and Lamivudine.90 of their children who were positive for HBV-DNA were randimly dinded into three groups,one group were treated by hepatitis B Vaccine,the second group were treated by hepatitis B Vaccine and HBIG,the third group were treated by hepatitis B Vaccine and Gm-CSF. Their serum HBV-DNA were tested by fluorescence quantitative - PCR method.Results After treatment on the fathers or mothers,the degree of HBV-DNA was decreased obviously. There were significant difference between the groups who were treated by HBIG and lamivudine and the group who were treated only by HBIG or lamivudine( P ＜0.05 ). The rate of their newborn with HBV-DNA( + ) were significantly lower then other groups. After treatment on the newborn with HBV-DNA( + ). The degree of HBV-DNA had significant difference between the groups who were treated by both drug and vaccine and the vaccine group(P ＜0.05). Conclusion The fathers or mothers with HBV-DNA( + ) were treated by HBIG、lamivudine before they want a child, and fheir newborn with HBV-DNA( + ) were treated by vaccine、HBIG、Gm-CSF. This was an important way to block the father-child、mother-child transmission of Hepatitis B Virus.

Objective To investigate the effect of poractant alfa injection(PS) on neonatal respiratory distress syndrome(NRDS).Methods According to the digital table,80 cases of NRDS were randomly divided into the control group (40 cases) and the treatment group (40 cases).Both two groups were treated by mechanical ventilation and conventional symptomatic,supportive treatment.The treatment group was given PS intratracheal injection,the control group was given 0.9％ sodium chloride injection intratracheal injection.The clinical symptoms,blood gas analysis and the improvement of X-ray chest film were dynamicly observed,the clinical efficacy was compared between the two groups.Results In the treatment group,PaO2 returned to ＞ 60mmHg time,PaCO2 returned to ＜ 50mmHg time,mechanical ventilation time were (2.13 ± 0.21) h,(12.56 ± 0.11) h,(18.2 ± 0.33) h,which were shorter than those in the control group [(12.41 ± 0.13) h,(89.87 ± 0.26) h,(76.13 ± 0.65) h,t =2.632,2.403,1.895,all P ＜ 0.05] ;39 cases in the treatment group were cured(97.5％),30 cases in the control group were cured(75.0％),the difference of cure rate between the two groups was statistically significant(x2 =8.53,P ＜ 0.05).The incidence rate of comnplications such as pulnonary hemorrhage,pneumothorax,intracranial hemorrhage in the treatment group was 7.5％,which was significantly lower than 32.5％ in the control group (x2 =7.81,P ＜ 0.05).Conclusion PS in the treatment of NRDS has obvious curative effect and less adverse reactions,it can be used in clinical application.

Objective To study the intervention effect of montelukast on thymus and activation-regulated chemokine(TARC) in the children with asthma.Methods 100 children with asthma were randomly divided into montelukast (LTRA) group ( n = 50) and budesonide (BUD) group ( n = 50), the LTRA group was treated with montelukast, the BUD group was treated with budesonide,50 children without asthma as control group were inhaled NS.Before and after 7 days treatment,the asthma symptoms, FEV1,concentration of TARC were measured.Results Before treatment,the concentration of TARC in asthma group was significantly higher than control group (P < 0.05 ).After treatment, the concentration of TARC in BUD group and LTRA group was significandy decreased( P < 0.05 ), but the difference between these two groups was not significantl( P > 0.05 ), the concentration of TARC in control group was not significantly decreased(P > 0.05 ) ;the symptoms were better after treatment in BUD group and LTRA group,(P <0,05) ,and the pulmonary function was significantly improved after treatment in BUD group and LTRA group ( P < 0.05 ).Conclusion TARC was the important factor in children asthma.Montelukast could block the production of TARC ,and was more convenient and safe for children asthma.